Mindpeak News | Mindpeak’s PD-L1 CPS AI to identify more patients for checkpoint therapy in gastric cancer at pathologist-level interobserver concordance

October 18, 2024

Mindpeak’s PD-L1 CPS AI to identify more patients for checkpoint therapy in gastric cancer at pathologist-level interobserver concordance

Our study, presented at ASCO 2024, investigated the use of AI-based software to assess PD-L1 expression in gastric cancer. The AI demonstrated a higher agreement with pathologists than pathologists with each other, while classifying more patients as eligible for immunotherapy.

Specifically, the AI showed a higher correlation and better concordance (+15%, p<0.05) in classifying patients than pathologists. Overall, the AI detected over 50% more positive cases (46 vs. 30.3), suggesting that the application of AI could help identify more patients eligible for targeted PD-L1 therapy.

‍

You may also be interested in

July 24, 2025

Mindpeak Featured in Ada Ventures’ Bio‑Infrastructure Spotlight

Find out more about our AI-based diagnostics

Mindpeak is committed to protecting and respecting your privacy. We use your personal data solely for managing your account and providing the products and services you have requested from us. From time to time, we would like to inform you about our products and services, as well as other content that may be of interest to you. If you agree to be contacted for this purpose, please indicate below how you would like us to reach you:

I agree to receive other communications from mindpeak.

You can unsubscribe from these notifications at any time. For more information on how to unsubscribe, our privacy practices, and how we protect and respect your privacy, please refer to our Privacy Policy.

By clicking “Submit” below, you consent to Mindpeak storing and processing the personal data you have provided above in order to deliver the requested content to you.Indem Sie unten auf „Einsenden“ klicken, stimmen Sie zu, dass Mindpeak die oben angegebenen persönlichen Daten speichert und verarbeitet, um Ihnen die angeforderten Inhalte bereitzustellen.
‍

Thank you!
Your submission has been received.

Oops! Something went wrong while submitting the form.

Mindpeak Breast IHC being displayed on a monitor

About Mindpeak

We build automation tools for visual diagnosis using state-of-the-art artificial intelligence and deep learning. Our tools assist cancer experts in providing reliable and reproducible diagnoses.
‍
This frees specialists from tedious, repetitive tasks such as quantification of cells or biomarkers and allows them to focus on tasks where their human expertise is indispensable. Explainable AI (xAI) results provide the required trust of pathologists into our tools.

Contact us

Mindpeak GmbH
Zirkusweg 2
20359 Hamburg
Germany
Email: info@mindpeak.ai
Telephone: +49 40 35 67 67 97

Regulatory Note:
Unless otherwise stated all products are intended for Research Use Only, not for use in diagnostic procedures.

Supported by:

Terms & Conditions

Contact

Mindpeak’s PD-L1 CPS AI to identify more patients for checkpoint therapy in gastric cancer at pathologist-level interobserver concordance

You may also be interested in

Find out more about our AI-based diagnostics

About Mindpeak

Company information

Contact us